2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.11 Lebeck Lee

PP01.11 Lebeck Lee - Abstract

Pdf Summary

The study focused on investigating the dynamics of circulating tumor DNA (ctDNA) in patients with relapsed small cell lung cancer (SCLC) to predict clinical outcomes. Researchers analyzed ctDNA in 95 blood samples from 20 unique patients with relapsed SCLC, comparing those who cleared their ctDNA early during treatment versus those who did not. The study also looked at the correlation between changes in peak variant allele frequency (VAF) of ctDNA and patient outcomes. Results showed that patients who cleared their ctDNA early had improved progression-free survival (PFS) and overall survival (OS) compared to those who did not. Specifically, the median OS was 7.4 months versus 3.7 months, and the median PFS was 5.2 months versus 1.8 months, respectively. Additionally, patients with a 50% reduction in on-treatment peak VAF had better PFS outcomes. The findings suggest that early clearance of ctDNA may be a prognostic indicator in relapsed SCLC patients and could indicate the need for a change in therapy for those who do not clear their ctDNA. This study highlights the potential value of ctDNA analysis in guiding treatment decisions for patients with relapsed SCLC.

Keywords

circulating tumor DNA

ctDNA

small cell lung cancer

relapsed SCLC

clinical outcomes

variant allele frequency

progression-free survival

overall survival

prognostic indicator

treatment decisions